Sun, Dec 28, 2014, 10:42 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • calvincbr calvincbr Jan 15, 2014 1:09 PM Flag

    The Momentum Continues for Galena Biopharma

    In late November of last year, Oppenheimer issued an outperform rating on Galena Biopharma with a 12 – 18 month price target of $6 per share. The research firm assigned the $6 price target strictly based on the potential of NeuVax. Oppenheimer estimates the potential market size at $5 billion. With shares now having blasted through the $6 price target, it’s likely that Oppenheimer will take a second look at the company’s other products/trials and assign a more accurate price target. In addition to Oppenheimer, several other firms have also been adjusting their valuations on Galena Biopharma during the first few weeks of 2014. Those firms include:

    •Piper Jaffray – $7 price target on January 7
    •Maxim – $9 price target on January 8
    •Roth Capital – $11 price target on January 13

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Regardless of PT, Galena's pipeline and management are strong, Abstral sale about to kick butt, and more institutional accumulation is going to push us UP IMO.

      New PTs could come out any day, and all that do for the next few weeks will be double digits considering Galena's pipeline.

      Sentiment: Hold

    • Hopefully it will get back to the 7-8 range soon

      Sentiment: Strong Buy

    • Abstral has another major benefit that seems to be missed by the investor and analyst community. That benefit is that Abstral sales may eventually be sufficient to fund the entire company’s research and development program. Given the depth and potential of Galena’s pipeline, that would be a huge relief for shareholders as they would no longer have to fear dilution.

      Sentiment: Hold

1.53+0.04(+2.68%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.